Our analysis examining empagliflozin vs dapagliflozin in Stage 3 CKD for kidney outcomes in TriNetX database. Led by @Joyita_4, a formal fellow at @bu_bmc_renal , during her second year of fellowship. @The_BMC@BioMedCentral
https://t.co/jwYtZ4PLJo
Congratulations to our graduating @bu_bmc_renal Nephrology Fellows! We are so proud of your hard work, dedication, and compassion throughout your fellowship. Wishing you all continued success in your next chapter! @connoroneilldee@SanthoshiBavi@SophieClaudel
@NephRodby@CharuThakar@kidney_boy I thought the signals from earlier French trials on avoiding RRT at least made some sense. But, this one is statistically negative for RRT too- possible 3.9% numerical benefit for HCO3 didn’t reach statistical significance.
Another win for IgAN https://t.co/Vafnx8GPmm @TheLancet Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Congratulations to our second year fellow Dr. Jaeine Lee for receiving the @BUmedical McCahan Day “Best resident/fellow abstract award” for her project with @DeepthiGunasek1 “Integrating POCUS curriculum into a Fourth year Internal Medicine Internship Preparation Course”. 🎉👏🎈
Most kidney trials whisper.
This one doesn’t.
@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.
eGFR at 39 weeks: -1.0% vs -7.7%.
Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis
Now online: The largest global validation of AHA PREVENT & ESC SCORE2 cardiovascular risk tools. Across ~6.5M people, both performed comparably across geographies & albuminuria further improved risk prediction
Open access in @NatureMedicine:
https://t.co/HiSjXc01rI
Presented at #ISNWCN:
Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy. Full phase 3 APPLAUSE-IgAN trial results: https://t.co/RD5a9ILL7X
@ISNWCN
Why should IM residents consider a career in Nephrology
Gen Neph clinic today
- Genetic testing for type IV collagen gene variants
- Perc vs lap PD cath placement
- GDMT for DKD
- Preemptive kidney tx
- Parathyroidectomy
- AMKD
- Sibeprelimab for IgAN
- Dialysis modality ed
Intern: The nephrology consult says to try a higher dose of lasix.
Attending: OK, does it say a specific dose or schedule?
Intern: 1 gram/24 hours
Attending: 🤯🤯🤯 What ⁉️💦💦💦
In adults with type 1 diabetes and chronic kidney disease with albuminuria, the decrease in the urinary albumin-to-creatinine ratio was significantly greater with finerenone than with placebo. Full phase 3 FINE-ONE trial results: https://t.co/E2ThxUUtfX
Editorial: Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer? https://t.co/xUQ07dMJwt
Albuminuria is common across cardiovascular–kidney–metabolic (CKM) phenotypes in the U.S. 🇺🇸
Using NHANES 2011–2020 (Diabetes, Obesity and Metabolism), we show:
• 11% with diabetes alone
• 7% with HTN alone
• >50% with advanced CKM phenotypes https://t.co/aek7r2wgde @SophieClaudel@waikarss@bu_bmc_renal
Epoetin: From life-saving to dangerous therapy in dialysis 1989-2005
This is a clinical history of the 5th biologic protein approved by the FDA under the brand name EPOGEN. Use of epoetin had an immediately life-saving impact on management of anemia in CKD patients. 1/
https://t.co/xNHcH8G1VH
Today’s trainees will define the future of medicine. Our survey exposes gaps in trainee awareness of transplant barriers for undocumented immigrants—showing why equity-focused training is essential. Kudos to @KatieRizzolo for conceiving this work.
Important analysis. We greatly overestimate the benefit SGLT2i drugs have for low risk populations.
For CKD progression in non-DM with UACR <200 mg/g, effective was 0.16 less events/100 pt-yr; less deaths 0.3/100 pt-yr; hospitalization ARR 3.1/100 pt-yr (largely HF pts).